07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas and...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Curna Inc., Opko deal

Opko Health acquired Curna for $10 million in cash. Curna's AntagoNAT drug discovery platform up-regulates therapeutic proteins through interference with non-coding RNAs. Curna spun out of and subsequently licensed the technology from the Scripps Research...